Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. histopathological
Show results for

Refine by

Histopathological Articles & Analysis

29 news found

DMS in Rapid Identification of Brain Tumours

DMS in Rapid Identification of Brain Tumours

In the future, DMS could provide an alternative to the current method of histopathological analysis of frozen sections. The disadvantages of the current method include subjectivity and the fact that genetic alterations may remain undetected. ...

ByOlfactomics


Liposomal Bupivacaine (Bupigel) Demonstrates Minimal Local Nerve Toxicity in a Rabbit Functional Model

Liposomal Bupivacaine (Bupigel) Demonstrates Minimal Local Nerve Toxicity in a Rabbit Functional Model

In this study we assessed Bupigel neurotoxicity on rabbit sciatic nerve using histopathology and electrophysiologic testing. Sciatic nerves of both hind limbs were injected dropwise with different formulations. ...

ByVirpax Pharmaceuticals


Teva and MODAG Announce Licensing Collaboration for Neurodegenerative Disease Drug Candidate

Teva and MODAG Announce Licensing Collaboration for Neurodegenerative Disease Drug Candidate

” Multiple System Atrophy Multiple system atrophy (MSA) is a rare neurodegenerative disorder classified clinically as "atypical parkinsonism" and belongs to the group of synucleinopathies. MSA is characterized histopathologically by abnormal deposits of the α-synuclein protein, mainly in oligodendroglial cells (glial cytoplasmic inclusions) and also in certain nerve ...

ByMODAG GmbH


The Lancet Oncology: 66% of diagnostic biopsies for common skin cancer can be avoided using Michelson Diagnostics’ VivoSight OCT laser scanner

The Lancet Oncology: 66% of diagnostic biopsies for common skin cancer can be avoided using Michelson Diagnostics’ VivoSight OCT laser scanner

This makes it extremely cost-effective as biopsy, histopathology and separate consultations are not ...

ByMichelson Diagnostics Ltd. (MDL)


Todd C. Villines, M.D. Joins Elucid as new Chief Medical Officer

Todd C. Villines, M.D. Joins Elucid as new Chief Medical Officer

Elucid is the first FDA-Cleared and CE-marked non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core. The company has published studies for its derivation of fractional flow reserve (FFRct) based on the vasodilative capacity of the vessel wall and estimation of coding and non-coding RNA transcripts ...

ByElucid


Elucid Raises $27 Million Series B Funding Round to Commercialize a New Paradigm in Heart Disease Diagnosis

Elucid Raises $27 Million Series B Funding Round to Commercialize a New Paradigm in Heart Disease Diagnosis

” “Elucid’s basis in histopathology is highly differentiated from competitive methods and is paramount to understanding the key drivers of atherosclerosis which cause ischemia and heart attacks,” said John Fichthorn of MedTex Ventures. ...

ByElucid


Sonia Madigan of the Market Herald interviews CEO Wayne Paterson on the progress of Anteris Technologies

Sonia Madigan of the Market Herald interviews CEO Wayne Paterson on the progress of Anteris Technologies

Conduits treated with the Adapt process showed no evidence of calcification as indicated by histopathology. The company said the results further validate its anti-calcification properties in highly problematic areas of surgery. ...

ByAnteris Technologies Limited


PAVmed PAVmed Provides Business Update and Preliminary First Quarter 2022 Financial Results

PAVmed PAVmed Provides Business Update and Preliminary First Quarter 2022 Financial Results

EsoCure development progressing well with favorable head-to-head histopathologic performance compared to market leading esophageal ablation device. ...

ByPAVmed Inc.


The largest breast AI study to date shows value of Transpara in mammographic screening

The largest breast AI study to date shows value of Transpara in mammographic screening

To fill this gap, the Registry compared Transpara's performance with routine independent double reading with consensus as usually performed in a population-based screening program. Further, they explored histopathological characteristics of tumours with different Transpara scores. ...

ByScreenPoint Medical


4D Path, PathPresenter Announce Partnership to Advance AI-enabled Digital Pathology for End-to-End Breast Tumor Profiling

4D Path, PathPresenter Announce Partnership to Advance AI-enabled Digital Pathology for End-to-End Breast Tumor Profiling

PathPresenter, a pioneer in the development of digital pathology software, and 4D Path Inc., developer of a pan-cancer diagnostic and precision oncology platform enabling AI-based biomarker typing and prognostication from H&E images, are announcing today a global partnership to distribute 4D Q-plasia OncoReader Breast within PathPresenter’s new Clinical Workflow Platform, ClinPx. 4D ...

By4D Path Inc.


Blue Earth Diagnostics Announces Key Results from Phase 3 SPOTLIGHT Study of iaF-rhPSMA-7.3, an Investigational PET Imaging Agent, in Biochemical Recurrence of Prostate Cancer

Blue Earth Diagnostics Announces Key Results from Phase 3 SPOTLIGHT Study of iaF-rhPSMA-7.3, an Investigational PET Imaging Agent, in Biochemical Recurrence of Prostate Cancer

The study was designed to confirm positive F-rhPSMA-7.3 PET imaging findings using a composite Standard of Truth (SoT) consisting of either: histopathology (considered the gold standard); or conventional imaging (primarily with CT, bone scan or MRI, with fewer procedures using 18F-fluciclovine PET). In 366 men with a composite SoT (histopathology and/or ...

ByBlue Earth Diagnostics


Blue Earth Diagnostics Highlights Axumin (Fluciclovine F 18) Presentation at Upcoming 22nd Annual Scientific Meeting in Urologic Oncology (SUO)

Blue Earth Diagnostics Highlights Axumin (Fluciclovine F 18) Presentation at Upcoming 22nd Annual Scientific Meeting in Urologic Oncology (SUO)

Clinical correlation, which may include histopathological evaluation, is recommended. Hypersensitivity reactions, including anaphylaxis, may occur in patients who receive Axumin. ...

ByBlue Earth Diagnostics


Elucid announces American Medical Association (AMA) instates CPT Code for Lipid-Rich Necrotic Core Quantification to Assess Atherosclerotic Plaque Stability

Elucid announces American Medical Association (AMA) instates CPT Code for Lipid-Rich Necrotic Core Quantification to Assess Atherosclerotic Plaque Stability

ElucidVivo is the first FDA-Cleared and CE-marked non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core. The company has published studies for its derivation of fractional flow reserve (FFRct) based on the vasodilative capacity of the vessel wall and estimation of coding and non-coding RNA ...

ByElucid


Neurona Therapeutics to Present New Preclinical Data and Clinical Trial Plans for Lead Neural Cell Therapy Program, NRTX-1001, at the Annual Meeting of the American Epilepsy Society

Neurona Therapeutics to Present New Preclinical Data and Clinical Trial Plans for Lead Neural Cell Therapy Program, NRTX-1001, at the Annual Meeting of the American Epilepsy Society

Daily observations and assessments of histopathology, hematology and clinical chemistries at multiple time points post-transplantation did not indicate adverse behavioral effects, or local or systemic toxicities related to NRTX-1001 treatment. ...

ByNeurona Therapeutics


Elucid Eyes Big Opportunity to Save Lives with Software Amidst Major Guideline Changes

Elucid Eyes Big Opportunity to Save Lives with Software Amidst Major Guideline Changes

ElucidVivo is the first FDA-Cleared and CE-marked non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core. The company recently published studies for its derivation of fractional flow reserve (FFR-CT) based on the vasodilative capacity of the vessel wall and estimation of coding and non-coding RNA ...

ByElucid


Elucid Presents Data Demonstrating Its AI Software Can Uniquely Quantify Key Drivers of Heart Attack and Stroke from Computed Tomography

Elucid Presents Data Demonstrating Its AI Software Can Uniquely Quantify Key Drivers of Heart Attack and Stroke from Computed Tomography

However, in the study “Intraplaque Hemorrhage and Lipid-Rich Necrotic Core may be Objectively Quantified using Histopathologic Correlates Automatically from CTA,” delineation of IPH is reported for the first time by any software. ...

ByElucid


Studies suggest Elucid’s AI software helps to objectively quantify key drivers of stroke and heart attack from computed tomography angiography (CTA)

Studies suggest Elucid’s AI software helps to objectively quantify key drivers of stroke and heart attack from computed tomography angiography (CTA)

“What our technology does, and what we are pleased to be working on, is a way to make that more specific to be able to discriminate tissues that have histopathologic correlates, and the importance of that is twofold,” Buckler said. ...

ByElucid


Elucid Secures $8 Million in Series A Funding Led by MedTex Ventures and Global Health Impact Fund

Elucid Secures $8 Million in Series A Funding Led by MedTex Ventures and Global Health Impact Fund

ElucidVivo is the first FDA-Cleared and CE-marked non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core. The company recently published studies for its derivation of fractional flow reserve (FFRct) based on the vasodilative capacity of the vessel wall and estimation of coding and non-coding RNA ...

ByElucid


Elucid Presents Results of the EVAPORATE Study at ESC Preventive Cardiology 2021 Late Breakers

Elucid Presents Results of the EVAPORATE Study at ESC Preventive Cardiology 2021 Late Breakers

ElucidVivo is the first FDA-Cleared and CE-marked non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core, and derives fractional flow reserve based on the vasodilative capacity of the vessel wall. ...

ByElucid


SEngine Precision Medicine Presents Data at 2021 AACR Annual Meeting Demonstrating Clinical Utility and Predictive Value of PARIS Test in Ovarian Cancer

SEngine Precision Medicine Presents Data at 2021 AACR Annual Meeting Demonstrating Clinical Utility and Predictive Value of PARIS Test in Ovarian Cancer

In an ovarian cancer cohort of 44 evaluable patient samples, authors found that: Ovarian cancer patient-derived 3D cultures preserve the histopathological and molecular features of original tumor samples. For 82% of patient samples tested, the PARIS® Test identified at least one drug with good to exceptional response that is either FDA approved or in clinical trials. ...

BySEngine Precision Medicine

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT